keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference - Day 2
keyboard_arrow_leftSearch & Filter
search
Streams
Main Conference - Day 2
search
Streams
7:00am - 7:45am45 mins
Registration and Coffee
7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 1
Guiding mRNA formulations from laboratory into clinical trials. Lessons learned from development and optimization of liposomal formulations.
- Andreas Wagner - Head of Liposome Technology, Polymun Scientific GmbH
7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 3
NOF Breakfast Spotlight Presentation
7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 2
LGC’s Development of a Novel, Modular, GalNAc Cluster Access, and Conjugation Strategies for Nucleic Acid Medicines
- Catherine McKeen, Ph.D. - Site Operational Director/Head of Chemistry, LGC Biosearch Technologies
- Juergen Mueller, Ph.D. - Commercial and Strategic Development Director Oligo-therapeutics, LGC Axolabs
8:20am - 8:25am5 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Chairperson's Remarks
- Jesper Lau, Ph.D. - Vice President, Protein and Peptide Chemistry, Novo Nordisk A/S
8:25am - 8:30am5 mins
Track 7: Partnering
Chairperson's Remarks
8:25am - 8:30am5 mins
Track 6: Drug Delivery Innovations and Strategies
Chairperson's Remarks
- Stephen Spagnol, PhD - Senior Scientist, Large Molecule Drug Product Development, Johnson & Johnson
8:25am - 8:30am5 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Chairperson's Remarks
- Claus Rentel, PhD - Executive Director, Analytical Development/QC, Ionis Pharmaceuticals, Inc.
8:25am - 8:30am5 mins
Track 5: mRNA Therapeutics and Genome Editing
Chairperson's Remarks
- James Thompson, PhD - CMC Therapeutic Area Lead, Moderna Therapeutics
8:25am - 8:30am5 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Chairperson's Remarks
- Arthur Levin, PhD - Executive Vice President, R&D, Avidity Biosciences LLC
8:25am - 8:30am5 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Chairperson's Remarks
- Christopher McGee, Ph.D. - Sr. Director, Business Development, Bachem
8:25am - 8:50am25 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Protein Manufacturing in Hours
- Bradley Pentelute, PhD - Professor, Chemistry, Massachusetts Institute of Technology
8:30am - 9:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
mRNA Technology for Rapid Response to Pandemic Threats
- Amy Jenkins - Program Manager, DARPA Biological Technologies Office
8:30am - 9:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Emerging RNA Delivery Technologies and Targeted Delivery
- Vadim Dudkin - Senior Director & Head, RNA & Targeted Thera, Janssen R&D
8:30am - 9:00am30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Pegcetacoplan – How an Efficient and Cost-Effective Commercial Manufacturing Process for a PEG-ylated Peptide Can Be Implemented at the Ton Scale?
- Philipp Wenter, Ph.D. - Senior Director of Drug Substance Manufacturing, Technical Operations, Apellis Pharmaceuticals
8:30am - 9:00am30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Regulatory Considerations for Setting Smart Starting Material Specifications
- Dominik Altevogt - Pharma Technical Regulatory Manager, F.Hoffmann-La Roche Ltd
8:30am - 9:30am60 mins
Track 7: Partnering
Panel Discussion: Streamlining the transition from discovery to manufacturing
- Matthias Schroff, Ph.D. - Chief Operating Officer, Exicure
- Andrew Latham, Ph.D. - Director, BD and Licensing, Merck
8:30am - 9:00am30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Predicting and Detecting Hybridization Dependent Events : A Rapidly Evolving Story
- Arthur Levin, PhD - Executive Vice President, R&D, Avidity Biosciences LLC
8:50am - 9:15am25 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Application of Diselenide-selenoester Ligation towards the Synthesis of Phosphorylated IGFBP-2
- Bhavesh Premdjee, Ph.D. - Senior Scientist, Research Chemistry, Novo Nordisk A/S
9:00am - 9:30am30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Phase Appropriate Analytical Control Strategies for Oligonucleotides
- Jessica Stolee, PhD - Associate Director, Pharma and ASO Analytical Deve, Biogen
9:00am - 9:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
mRNA Therapy for Inherited Disorders of Glycogen Metabolism
- Paloma Giangrande - Director of Research, Moderna Therapeutics
9:00am - 9:30am30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Strategies for Investigation and Control of Peptide Process-Related Impurities in APIs coming from Raw Materials through the Up-scaling Manufacturing Process
- El Djouhar Rekaï, PhD - Head of Development & Manufacturing Process, PolyPeptide Group
9:00am - 9:30am30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Assessing Therapeutic Oligonucleotide Selectivity with RNA-seq
- Sebastien Burel, PhD - Executive Director, Nonclinical Development, Ionis Pharmaceuticals
9:00am - 9:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
Precision Polymer Architectures and Molecular Conjugates to Enable Nucleic Acid and Peptide Therapeutics Against Undruggable Targets
- Craig Duvall, Ph.D. - Cornelius Vanderbilt Professor of Biomedical Engineering, Vanderbilt University
9:15am - 9:40am25 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Phage Display Selection of Peptides that Resist Proteases in the Gastrointestinal Tract
- Vanessa Carle - Postdoctoral Researcher, EPFL (École polytechnique fédérale de La
9:30am - 10:00am30 mins
Track 7: Partnering
Success Story: Case Study of a Successful Product Deal
9:30am - 10:00am30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Identifying and Avoiding RISC Mediated Off-Target Events
- Maja Janas, Ph.D. - Senior Scientist, Investigative Toxicology, Alnylam Pharmaceuticals
9:30am - 10:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Genetic Reprogramming of TAMs by Engineered Exosomes Results in Potent Single Agent Anti-tumor Activity
- Sriram Sathy, Ph.D. - Vice President, Biology and Translational Medicine, Codiak Biosciences
9:30am - 10:00am30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Tozuleristide (BLZ-100): Developing an FGS Imaging Agent – How Hard can it Be?
- Claudia Jochheim, Ph.D. - SVP, Process Development & Manufacturing, Blaze Bioscience, Inc.
9:30am - 10:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Targeted Degradation of Therapeutic Targets Using bioPROTAC mRNA
- Anthony Partridge, PhD - Senior Principal Scientist, Quantitative Biosciences, MSD International
9:30am - 10:00am30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Characterization of the Diastereoisomeric Composition of Phosphorothioate Oligonucleotides
- Claus Rentel, PhD - Executive Director, Analytical Development/QC, Ionis Pharmaceuticals, Inc.
9:40am - 10:05am25 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Peptide Display
- Akane Kawamura, Ph.D. - Research Fellow, University Of Oxford
10:00am - 10:45am45 mins
Track 7: Partnering
Networking and Refreshment Break in Poster and Exhibit Hall
10:00am - 10:45am45 mins
Track 5: mRNA Therapeutics and Genome Editing
Networking and Refreshment Break in Poster and Exhibit Hall
10:00am - 10:45am45 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Networking and Refreshment Break in Poster and Exhibit Hall
10:00am - 10:45am45 mins
Track 6: Drug Delivery Innovations and Strategies
Networking and Refreshment Break in Poster and Exhibit Hall
10:00am - 10:45am45 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Networking Refreshment Break in Poster and Exhibit Hall
10:00am - 10:45am45 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Networking and Refreshment Break in Poster and Exhibit Hall
10:05am - 10:45am40 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Networking Refreshment Break in Poster and Exhibit Hall
10:45am - 11:15am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Precisely Engineered Stealth mRNAs for Oncolytic mRNA Immunotherapy
- Yusuf Erkul - Co-founder & President, Kernal Biologics
10:45am - 11:15am30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
An Approach to Process Validation for Peptides
- Matteo Villain, Ph.D. - Vice President of CMC, Bachem Americas
10:45am - 11:15am30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Presentation Title TBA
- Matthias Kretschmer, Ph.D. - Senior Director Analytical Sciences, Alnylam Pharmaceuticals
10:45am - 11:45am60 mins
Track 7: Partnering
Panel Discussion: Deals that matter: Partnering with platform technologies: Trends, models and challenges.
- Cory Sago - Head of Platform Research, Guide Therapeutics
- Michael Torres - Director of Biology, coFounder, ReCode Therapeutics
10:45am - 11:15am30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Detection and Prediction of Transcriptome-wide Off-target Effects Caused by Steric Blocking Oligonucleotides
- Amit Deshwar - Director of Predictive Systems, Deep Genomics
10:45am - 11:15am30 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Platforms for the Generation and High-throughput Screening of Microcycle Libraries for Inhibitors Protein-protein and Protein-DNA Interactions
- Ali Tavassoli, Ph.D. - CSO, Curve Therapeutics, University of Southampton
10:45am - 11:15am30 mins
Track 6: Drug Delivery Innovations and Strategies
Non-viral Delivery of CRISPR-Cas9 Ribonucleoproteins ex vivo and in vivo
- Krishanu Saha - Associate Professor, University of Wisconsin-Madison
11:15am - 11:45am30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Mind the Gap: Bridging Drug Substance and Drug Product Analytical Methods
- David Benstead, Ph.D. - Senior Analytical Scientist, AstraZeneca
11:15am - 11:45am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Designing Formulations to Enable a Broad Portfolio of mRNA Medicines
- Luis Brito, Ph.D. - Director, Formulation Design, Moderna Therapeutics
11:15am - 11:45am30 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Endosomal Escape Vehicles and Their Mechanism of Action
- Dehua Pei, PhD - Professor, Department of Chemistry and Biochemistry, Ohio State University
11:15am - 11:45am30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Late Breaking Presentation
11:15am - 11:45am30 mins
Track 6: Drug Delivery Innovations and Strategies
Novel Delivery Methods for Nucleic Acids
- Jessica Rouge, PhD - Assistant Professor of Chemistry, University of Connecticut
11:15am - 11:45am30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Bioinformatics Approaches to Avoiding and Identifying Off-target Events
- Adam Pavlicek - CEO, Monoceros Biosystems
11:45am - 12:15pm30 mins
Track 5: mRNA Therapeutics and Genome Editing
Considerations in mRNA Design to Generate Potent Prophylactic mRNA Vaccines
- Nicole Armbruster, Ph.D. - Scientist, CureVac AG
11:45am - 12:15pm30 mins
Track 7: Partnering
PartneringONE: Dedicated time for scheduled partnering meetings
11:45am - 12:15pm30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Panel Discussion with Session Speakers
11:45am - 12:15pm30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Software Implementation for Quality Control of Oligonucleotides by Mass Spectrometry
- Juliet Padden, Ph.D. - Lab Manager Mass Spectrometry, Bayer AG
11:45am - 12:15pm30 mins
Track 6: Drug Delivery Innovations and Strategies
Panel Discussion with Session Speakers
11:45am - 12:15pm30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Panel Discussion
- Raj Manchanda, Ph.D. - Chief Tech Ops Officer, Anokion US Inc.
11:45am - 12:15pm30 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Towards Universal Druggability with HeliconTM Peptides
- Howard Stern, M.D., Ph.D. - Chief Scientific Officer, Fog Pharmaceuticals
12:15pm - 12:20pm5 mins
Track 6: Drug Delivery Innovations and Strategies
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Track 5: mRNA Therapeutics and Genome Editing
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Track 7: Partnering
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Transition to Spotlight Presentation Rooms
12:20pm - 12:50pm30 mins
Spotlight Presentation 1
BioSpring Afternoon Briefing
- Hüseyin Aygün, Ph.D. - Chief Scientific Officer, BioSpring
12:20pm - 12:50pm30 mins
Spotlight Presentation 2
Generic Peptide Process Development in Support of ANDA Filings
- Lin Chen, PhD - Peptide Process Chemistry Group Leader, CordenPharma Colorado
12:20pm - 12:50pm30 mins
Spotlight Presentation 3
Nagase Afternoon Briefing
12:20pm - 12:50pm30 mins
Spotlight Presentation 4
A Single-Use Solution to Bulk Tray Lyophilization of Polypeptide and Oligonucleotide Therapeutics
- Scott Ross - Global Product Specialist, W.L. Gore & Associates
12:50pm - 1:55pm65 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Networking Luncheon in Poster and Exhibit Hall
12:50pm - 1:55pm65 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Networking Luncheon in Poster and Exhibit Hall
12:50pm - 1:55pm65 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Networking Luncheon in Poster and Exhibit Hall
12:50pm - 1:55pm65 mins
Track 6: Drug Delivery Innovations and Strategies
Networking Luncheon in Poster and Exhibit Hall
12:50pm - 1:55pm65 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Networking Luncheon in Poster and Exhibit Hall
12:50pm - 1:55pm65 mins
Track 7: Partnering
Networking Luncheon in Poster and Exhibit Hall
12:50pm - 1:55pm65 mins
Track 5: mRNA Therapeutics and Genome Editing
Networking Luncheon in Poster and Exhibit Hall
1:55pm - 2:00pm5 mins
Track 7: Partnering
Chairperson's Remarks
1:55pm - 2:00pm5 mins
Track 5: mRNA Therapeutics and Genome Editing
Chairperson's Remarks
- James Thompson, PhD - CMC Therapeutic Area Lead, Moderna Therapeutics
1:55pm - 2:00pm5 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Chairperson's Remarks
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, Inc.
1:55pm - 2:00pm5 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Chairperson's Remarks
- Trishul Shah, MS - Director Business Development, PolyPeptide Group
1:55pm - 2:00pm5 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Chairperson's Remarks
- G. Susan Srivatsa, PhD - President, ElixinPharma
1:55pm - 2:00pm5 mins
Track 6: Drug Delivery Innovations and Strategies
Chairperson's Remarks
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, Inc.
1:55pm - 2:00pm5 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Chairperson's Remarks
- Ali Tavassoli, Ph.D. - CSO, Curve Therapeutics, University of Southampton
2:00pm - 2:30pm30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Escape from the Endosome: We Need to Overcome a Billion-Year-Old Fortress!
- Steven Dowdy, Ph.D. - Professor, UCSD School of Medicine
2:00pm - 2:30pm30 mins
Track 6: Drug Delivery Innovations and Strategies
Escape from the Endosome: We Need to Overcome a Billion-Year-Old Fortress!
- Steven Dowdy, Ph.D. - Professor, UCSD School of Medicine
2:00pm - 3:00pm60 mins
Track 7: Partnering
Panel Discussion: Developing Relationships in the Investment Community
- Frédéric Legros - Chief Operating Officer, Dynacure
- Laszlo Kiss, Ph.D. - Executive Director, Pfizer Ventures
- David Greenwald - VP Business Development, Deerfield
2:00pm - 2:30pm30 mins
Track 5: mRNA Therapeutics and Genome Editing
Messenger RNA Therapeutics for Treating Disease
- Christian Plank, Ph.D. - Chief Technology Officer, Ethris GmbH
2:00pm - 2:30pm30 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Overview of CIPPS and Peptide Science in Australia
- Annie Kan, Ph.D. - Senior Research Administration Officer, University of Queensland
2:00pm - 2:30pm30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Solution Phase, Solid Phase and Hybrid Approaches to Peptide Synthesis - A Comparison
- Daniel Samson, PhD - Vice President, API SPPS, Bachem AG
2:00pm - 2:30pm30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
The Evolution of Regulation for Oligonucleotide Therapeutics: Regulatory Agency Perspectives
- René Thürmer, Ph.D. - Deputy Head, BfArM Federal Inst for Drugs & Med Device
2:30pm - 3:00pm30 mins
Track 6: Drug Delivery Innovations and Strategies
Targeted Delivery to Extrahepatic Tissues
- Jayaprakash Nair, Ph.D. - Associate Director, Research, Alnylam Pharmaceuticals
2:30pm - 3:00pm30 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Peptides in Food Science – Promoting Health and Assuring Safety
- Michelle Colgrave - Professor of Food and Agricultural Proteomics, CSIRO
2:30pm - 3:00pm30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Part 1: Process Strategy for the Manufacturing of Synthetic Peptides: Solid or Liquid Phase Strategy? Or Disruptive Method using Mechanochemistry
- Olivier Ludemann-Hombourger, PhD - Global Director Innovation and Strategy, PolyPeptide Group
2:30pm - 3:00pm30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Strategies for Identity Testing of Therapeutic Oligonucleotide Drug Substances and Drug Products
- Daniel Capaldi - Vice President Analytical & Process Development, Ionis Pharmaceuticals
2:30pm - 3:00pm30 mins
Track 5: mRNA Therapeutics and Genome Editing
The eTheRNA Immunotherapies’ Journey from Dendritic Cell Autologous Immunotherapeutics to a Novel Series of Oncology Off-the-shelf mRNA Products
- Bertil Lindmark - Chief Medical Officer, eTheRNA Immunotherapies
2:30pm - 3:00pm30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Targeted Delivery to Extrahepatic Tissues
- Jayaprakash Nair, Ph.D. - Associate Director, Research, Alnylam Pharmaceuticals
3:00pm - 3:30pm30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Targeted Delivery of ASOs beyond the Liver
- Punit Seth, PhD - Vice President, Medicinal Chemistry, Ionis Pharmaceuticals
3:00pm - 3:30pm30 mins
Track 7: Partnering
Building a Biotech: From Investment to IND and beyond
- Barry Kappel - Chief Executive Officer, Sapience Therapeutics
3:00pm - 3:30pm30 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Bringing Peptides to Market: Regula(tory) Rom-com or Horror movie?
- Nick Watts - Research Director, Innovate Ag
3:00pm - 3:30pm30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Part 2: Process Strategy for the Manufacturing of Synthetic Peptides: Solid or Liquid Phase Strategy? Or Disruptive Method using Mechanochemistry
- Frederic Lamaty, Ph.D. - Director of Research, Head of Green Chemistry Team, University of Montpelier
3:00pm - 3:30pm30 mins
Track 5: mRNA Therapeutics and Genome Editing
mRNA Clinical Update
- Allison August, MD - Senior Director, Clinical Development, Moderna Therapeutics
3:00pm - 3:30pm30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Industry Presentation on Lessons Learned from an Oligonucleotide Regulatory Approval
3:00pm - 3:30pm30 mins
Track 6: Drug Delivery Innovations and Strategies
Targeted Delivery of ASOs beyond the Liver
- Punit Seth, PhD - Vice President, Medicinal Chemistry, Ionis Pharmaceuticals
3:30pm - 4:15pm45 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Networking Refreshment Break in Poster and Exhibit Hall
3:30pm - 4:15pm45 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Networking Refreshment Break in Poster and Exhibit Hall
3:30pm - 4:15pm45 mins
Track 5: mRNA Therapeutics and Genome Editing
Networking Refreshment Break in Poster and Exhibit Hall
3:30pm - 4:15pm45 mins
Track 7: Partnering
Coffee/Networking Break
3:30pm - 4:15pm45 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Networking Refreshment Break in Poster and Exhibit Hall
3:30pm - 4:15pm45 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Networking Refreshment Break in Poster and Exhibit Hall
3:30pm - 4:15pm45 mins
Track 6: Drug Delivery Innovations and Strategies
Networking Refreshment Break in Poster and Exhibit Hall
4:15pm - 4:45pm30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
The Case for Chemo-enzymatic Synthesis (CEPS) in the Commercial Manufacture of Therapeutic Peptides
- Rodney Lax, Ph.D. - Business Development Consultant, Enzytag BV
4:15pm - 4:45pm30 mins
Track 3: Peptide Discovery, Preclinical and Clinical
The Commercial Development of a Peptide for Human Fungal Toenail Infections (Onychomycosis)
- Nicole Van Der Weerden - Chief Executive Officer, Hexima Ltd
4:15pm - 4:45pm30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Messenger RNA: Design and Manufacturing of a New Therapeutic Drug Class
- Anton McCaffrey, PhD - Senior Director of Emerging Science & Innovation, TriLink BioTechnologies, Inc.
4:15pm - 4:45pm30 mins
Track 5: mRNA Therapeutics and Genome Editing
Messenger RNA: Design and Manufacturing of a New Therapeutic Drug Class
- Anton McCaffrey, PhD - Senior Director of Emerging Science & Innovation, TriLink BioTechnologies, Inc.
4:15pm - 4:45pm30 mins
Track 7: Partnering
Fireside Chat: Case study of a Successful Investment Partnership
4:15pm - 4:45pm30 mins
Track 6: Drug Delivery Innovations and Strategies
Fatty-acid Conjugation Improves Functional Delivery of RNA therapeutics in the Eye
- Charles Allerson, Ph.D. - Vice President of Chemistry & Drug Development, DTx Pharma
4:15pm - 4:45pm30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Fatty-acid Conjugation Improves Functional Delivery of RNA therapeutics in the Eye
- Charles Allerson, Ph.D. - Vice President of Chemistry & Drug Development, DTx Pharma
4:45pm - 5:15pm30 mins
Track 5: mRNA Therapeutics and Genome Editing
Manufacturing and CMC Approaches to mRNA Therapeutics
- Christoph Kroener, Ph.D. - Head of Lead Structure and DNA Template Development for Individualized RNA Products, BioNTech AG
4:45pm - 5:15pm30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Manufacture of Long-chain Peptides in Highest Quality
- Christian Schwarz, PhD - CEO, Numaferm GmbH
4:45pm - 5:30pm45 mins
Track 7: Partnering
PartneringONE: Dedicated time for scheduled partnering meetings
4:45pm - 5:15pm30 mins
Track 3: Peptide Discovery, Preclinical and Clinical
How Do Anticancer Peptides Select and Enter Inside Tumor Cells?
- Sónia Henriques, Ph.D. - Senior Lecturer, School of Biomedical Sciences, Queensland University of Technology
4:45pm - 5:15pm30 mins
Track 6: Drug Delivery Innovations and Strategies
Targeted Delivery of Oligonucleotides
- Shalini Andersson, Ph.D. - Chief Scientist New Therapeutic Modalities, AstraZeneca
4:45pm - 5:15pm30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
Manufacturing and CMC Approaches to mRNA Therapeutics
- Christoph Kroener, Ph.D. - Head of Lead Structure and DNA Template Development for Individualized RNA Products, BioNTech AG
4:45pm - 5:15pm30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Targeted Delivery of Oligonucleotides
- Shalini Andersson, Ph.D. - Chief Scientist New Therapeutic Modalities, AstraZeneca
5:15pm - 5:45pm30 mins
Track 1: Oligonucleotide Discovery, Preclinical and Clinical
Panel Discussion
5:15pm - 5:45pm30 mins
Track 6: Drug Delivery Innovations and Strategies
Panel Discussion
5:15pm - 5:45pm30 mins
Track 4: Peptide Chemistry, Manufacturing and Controls
Panel Discussion with Session Speakers
5:15pm - 5:45pm30 mins
Track 2: Oligonucleotide Chemistry, Manufacturing and Controls
mRNA CMC Strategies
- Don Parsons, PhD - Head, Early Technical Development, Moderna Therapeutics
5:15pm - 5:45pm30 mins
Track 5: mRNA Therapeutics and Genome Editing
mRNA CMC Strategies
- Don Parsons, PhD - Head, Early Technical Development, Moderna Therapeutics
5:15pm - 5:45pm30 mins
Track 3: Peptide Discovery, Preclinical and Clinical
Toward Peptide-based Approaches for Safeguarding the Great Barrier Reef
- Conan Wang - Senior Research Officer, Institute for Molecular Bioscience, University of Queensland
5:30pm - 5:35pm5 mins
Track 7: Partnering
End of Day
5:45pm - 6:45pm60 mins
Networking Reception in Poster and Exhibit Hall
Get the latest news.
As it happens
Sign up to get the latest on the agenda and speakers.
Filter
Streams